Kezar Life Sciences (KZR) Q2 2025 earnings summary

Executive summary

• Focused on developing zetomipzomib for autoimmune hepatitis after terminating other clinical programs, with ongoing regulatory engagement following FDA removal of a clinical hold on a key trial in July 2025.

• Type C meeting with FDA requested for Q4 2025 to discuss registration-enabling trial design.

• PORTOLA Phase 2a data selected for oral presentation at The Liver Meeting 2025.

• Zung To promoted to Chief Development Officer, strengthening clinical development leadership.

• No product sales to date; operations funded by equity, debt, and a collaboration with Everest Medicines, with continued significant operating losses expected.

Financial highlights

• Net loss for Q2 2025 was $13.7 million, down from $21.5 million in Q2 2024; six-month net loss was $30.3 million, down from $43.2 million year-over-year.

• Operating expenses for Q2 2025 were $14.6 million, a decrease from $23.4 million in Q2 2024, mainly due to lower R&D and restructuring costs.

• Cash, cash equivalents, and marketable securities totaled $100.8 million as of June 30, 2025, down from $132.2 million at December 31, 2024.

• R&D expenses for Q2 2025 decreased to $9.6 million from $16.3 million in Q2 2024, mainly due to lower clinical activity and personnel costs.

• G&A expenses for Q2 2025 decreased to $5.0 million from $5.6 million in Q2 2024.

Outlook and guidance

• Cash resources are expected to fund operations for at least 12 months from the reporting date, but additional capital will be needed for long-term plans.

• Expenses are expected to remain stable in the near term, then increase as zetomipzomib advances into later-stage development.

• On track with clinical development and regulatory submission plan for zetomipzomib in autoimmune hepatitis.

• Type C FDA meeting in Q4 2025 expected to be a key milestone for advancing zetomipzomib.

• No revenue from product sales anticipated in the near future; future funding needs depend on clinical progress and regulatory outcomes.